Cidara Therapeutics (NASDAQ:CDTX) posted its earnings results on Thursday. The biotechnology company reported $0.08 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.34, Fidelity Earnings reports. The firm had revenue of $19.10 million during the quarter, compared to analyst estimates of $30.00 million.
Shares of CDTX traded up $0.09 during trading hours on Friday, reaching $2.38. 191,200 shares of the company traded hands, compared to its average volume of 219,611. The stock has a market capitalization of $61.03 million, a PE ratio of -1.03 and a beta of 2.12. The stock has a fifty day simple moving average of $1.97 and a 200 day simple moving average of $1.81. The company has a quick ratio of 2.57, a current ratio of 2.57 and a debt-to-equity ratio of 0.04. Cidara Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $4.20.
Several research firms have weighed in on CDTX. ValuEngine raised Cidara Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Needham & Company LLC set a $10.00 price objective on Cidara Therapeutics and gave the company a “buy” rating in a research note on Monday, August 12th. BTIG Research reaffirmed a “buy” rating and set a $7.00 price objective on shares of Cidara Therapeutics in a research note on Wednesday, September 4th. Wedbush raised Cidara Therapeutics from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $2.00 to $4.00 in a research note on Tuesday, September 3rd. Finally, Zacks Investment Research lowered Cidara Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. Cidara Therapeutics currently has an average rating of “Hold” and an average target price of $6.08.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.